1. Efficacy of Icotinib, an EGFR Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer Patients with Exon 19 Deletion and Exon 21 L858R: A Retrospective Analysis in China
   Yang Wang et al, 2021, Pharmacology CrossRef
2. Progastrin-Releasing Peptide Precursor and Neuron-Specific Enolase Predict the Efficacy of First-Line Treatment with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors Among Non-Small-Cell Lung Cancer Patients Harboring EGFR Mutations
   Juanjuan Dong et al, 2021, Cancer Management and Research CrossRef
3. Safety and Tolerability of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Oncology
   Rashmi R. Shah et al, 2019, Drug Safety CrossRef
4. Efficacy and adverse events of five targeted agents in the treatment of advanced or metastatic non‐small‐cell lung cancer: A network meta‐analysis of nine eligible randomized controlled trials involving 5,059 patients
   Gui‐Feng Liu et al, 2019, Journal of Cellular Physiology CrossRef
5. Icotinib: efficacy in different solid tumors and gene mutations
   Qian Zhao et al, 2020, Anti-Cancer Drugs CrossRef
6. Icotinib versus Cisplatin Plus Docetaxel as Adjuvant Chemotherapy in Patients with Stage II (N1+) Non-Small Cell Lung Cancer Harboring Positive EGFR Mutations: A Single-Center Retrospective Study
   Saibo Pan et al, 2021, OncoTargets and Therapy CrossRef
7. Novel 1,2,3-Triazole Erlotinib Derivatives as Potent IDO1 Inhibitors: Design, Drug-Target Interactions Prediction, Synthesis, Biological Evaluation, Molecular Docking and ADME Properties Studies
   Gui-Qing Xu et al, 2022, Frontiers in Pharmacology CrossRef
8. Clinical efficacy of icotinib in lung cancer patients with differentEGFRmutation status: a meta-analysis
   Jian Qu et al, 2017, Oncotarget CrossRef